Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin.
about
Effects of localized interactions and surface properties on stability of protein-based therapeutics.Glycosylation of the enhanced aromatic sequon is similarly stabilizing in three distinct reverse turn contextsIgA nephropathy caused by unusual polymerization of IgA1 with aberrant N-glycosylation in a patient with monoclonal immunoglobulin deposition disease.The influence of artificially introduced N-glycosylation sites on the in vitro activity of Xenopus laevis erythropoietin.In silico design and analysis of a new hyperglycosylated analog of erythropoietin to improve drug efficacy.Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.N-glycosylation of enhanced aromatic sequons to increase glycoprotein stabilityComparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome.High hematocrit resulting from administration of erythropoiesis-stimulating agents is not fully predictive of mortality or toxicities in preclinical species.Erythropoiesis stimulating agents: approaches to modulate activity.Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.N-glycan-mediated quality control in the endoplasmic reticulum is required for the expression of correctly folded delta-opioid receptors at the cell surface.Protein native-state stabilization by placing aromatic side chains in N-glycosylated reverse turns.Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy.A kinetic-metabolic model based on cell energetic state: study of CHO cell behavior under Na-butyrate stimulation.
P2860
Q30395368-4070DC9A-7EBF-43AA-83C7-7ECAF97476F4Q34028044-23BF5517-04BB-41EF-AF11-F7FE0121B63AQ35126705-DA633F77-FFBD-4601-9F4F-6BE5FFAEDFB9Q35610754-2B533478-E7D5-418C-8138-92C69EEDD0EAQ35997019-0E8A5C90-5E21-44BE-B929-AFB7EB38A1B7Q36131665-FF14ED09-01A0-4879-9377-5F6DD6B46FF7Q36157560-49AE8AEB-8FDB-43A1-BAB8-3E81A9A3D3EDQ36515262-E56E5108-6CA9-4093-AF73-7752BF8F6612Q37598414-9398DE25-8EB9-440C-BFAA-70BCAD50CD5FQ38106921-32CF8318-5270-4E8E-9DD7-A9A748552139Q38121067-68B7868E-95D0-45FD-8716-930327A00CD4Q40276435-6B29B535-054F-494D-AF0B-84E79E42E249Q41929065-20605876-C968-4CFC-8B31-E811E0C6F640Q42129538-843EB205-CD17-492F-9282-A701A5CEC531Q43591074-D4E24ABD-8826-46BB-ACB5-2B5562F58C92Q44828146-67E92131-67DF-4CF2-8C25-DCF85B181573
P2860
Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Structural requirements for ad ...... ombinant human erythropoietin.
@en
Structural requirements for ad ...... ombinant human erythropoietin.
@nl
type
label
Structural requirements for ad ...... ombinant human erythropoietin.
@en
Structural requirements for ad ...... ombinant human erythropoietin.
@nl
prefLabel
Structural requirements for ad ...... ombinant human erythropoietin.
@en
Structural requirements for ad ...... ombinant human erythropoietin.
@nl
P2093
P2860
P356
P1476
Structural requirements for ad ...... ombinant human erythropoietin.
@en
P2093
David Chang
Evelyne Delorme
Steve Elliott
Tamer Eris
Tony Lorenzini
P2860
P304
16854-16862
P356
10.1074/JBC.M311095200
P407
P577
2004-02-02T00:00:00Z